ARTICLE | Clinical News
CSL830: Ph III COMPACT data
April 12, 2017 12:53 AM UTC
The double-blind, crossover, international Phase III COMPACT trial in 90 Type I or II HAE patients showed that twice-weekly 40 and 60 IU/kg subcutaneous CSL830 each met the primary endpoint of reducin...
BCIQ Company Profiles
BCIQ Target Profiles